Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tg Therapeutics (TGTX) Net Margin (2016 - 2025)

Tg Therapeutics has reported Net Margin over the past 10 years, most recently at 43.96% for Q4 2025.

  • Quarterly results put Net Margin at 43.96% for Q4 2025, down 6634.0% from a year ago — trailing twelve months through Dec 2025 was 55.09% (up 4772.0% YoY), and the annual figure for FY2025 was 55.08%, up 4770.0%.
  • Net Margin for Q4 2025 was 43.96% at Tg Therapeutics, down from 241.73% in the prior quarter.
  • Over the last five years, Net Margin for TGTX hit a ceiling of 241.73% in Q3 2025 and a floor of 100501.25% in Q4 2022.
  • Median Net Margin over the past 5 years was 170.08% (2023), compared with a mean of 8769.4%.
  • Biggest five-year swings in Net Margin: surged 22771995bps in 2021 and later tumbled -9645015bps in 2022.
  • Tg Therapeutics' Net Margin stood at 4051.1% in 2021, then plummeted by -2381bps to 100501.25% in 2022, then skyrocketed by 100bps to 32.79% in 2023, then soared by 168bps to 22.38% in 2024, then tumbled by -296bps to 43.96% in 2025.
  • The last three reported values for Net Margin were 43.96% (Q4 2025), 241.73% (Q3 2025), and 19.97% (Q2 2025) per Business Quant data.